tetano
Editor, Senior Moderator
Euro Surveill. 2019 Feb;24(8). doi: 10.2807/1560-7917.ES.2019.24.1900121.
[h=1]Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019.[/h] Kissling E[SUP]1,[/SUP][SUP]2[/SUP], Rose A[SUP]1,[/SUP][SUP]2[/SUP], Emborg HD[SUP]3[/SUP], Gherasim A[SUP]4[/SUP], Pebody R[SUP]5[/SUP], Pozo F[SUP]6[/SUP], Trebbien R[SUP]7[/SUP], Mazagatos C[SUP]4[/SUP], Whitaker H[SUP]5[/SUP], Valenciano M[SUP]2[/SUP], European Ive Group[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018-January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32-43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34-38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.
[h=4]KEYWORDS:[/h] Europe; influenza; multicentre study; test-negative design; vaccination; vaccine effectiveness; vaccines and immunisation
PMID: 30808440 DOI: 10.2807/1560-7917.ES.2019.24.1900121
Free full text
[h=1]Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019.[/h] Kissling E[SUP]1,[/SUP][SUP]2[/SUP], Rose A[SUP]1,[/SUP][SUP]2[/SUP], Emborg HD[SUP]3[/SUP], Gherasim A[SUP]4[/SUP], Pebody R[SUP]5[/SUP], Pozo F[SUP]6[/SUP], Trebbien R[SUP]7[/SUP], Mazagatos C[SUP]4[/SUP], Whitaker H[SUP]5[/SUP], Valenciano M[SUP]2[/SUP], European Ive Group[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018-January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32-43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34-38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.
[h=4]KEYWORDS:[/h] Europe; influenza; multicentre study; test-negative design; vaccination; vaccine effectiveness; vaccines and immunisation
PMID: 30808440 DOI: 10.2807/1560-7917.ES.2019.24.1900121
Free full text